Bionano Genomics (STU:2Y30) Beta: 0.0379 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2Y30 Bionano Genomics Inc STU:2Y30
64 GF Score
Price €315.84
GF Value €422.95
! 3 Warning Signs
View Full Analysis

What is Bionano Genomics Beta?

Bionano Genomics STU:2Y30 64 Beta is 0.0379 as of Jul. 19, 2026. GuruFocus rates STU:2Y30 with a GF Score™ of 64/100 and a GF Value™ of €422.95. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-19), Bionano Genomics's Beta is 0.0379.


Bionano Genomics  (STU:2Y30) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Bionano Genomics Beta Related Terms


Bionano Genomics Beta Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Beta Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.34 -0.36 -0.04 0.88

Bionano Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.57 0.62 0.88 -0.03

STU:2Y30 vs UEEC, CUPR, FEMY: Beta Comparison

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Beta distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Beta falls into.


STU:2Y30
64GF Score
Bionano Genomics Inc STU:2Y30
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionano Genomics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0379 mean?
Bionano Genomics (STU:2Y30) has a Beta of 0.0379 as of Jul. 19, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bionano Genomics and its competitors.
Is Bionano Genomics' Beta too high?
Bionano Genomics' current Beta is 0.0379. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Beta compare to UEEC and CUPR?
Bionano Genomics' Beta of 0.0379 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bionano Genomics and its competitors. Bionano Genomics's current Beta is 0.0379. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (STU:2Y30) has a current Beta of 0.0379. The stock's GF Value™ is €422.95, compared to a current price of €315.84 — trading 25.3% below its estimated fair value. The current Beta is 0.0379. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Bionano Genomics (STU:2Y30), the current Beta is 0.0379 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionano Genomics (STU:2Y30) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued. The current stock price of €315.84 is trading 25.3% below its estimated GF Value™ of €422.95.

Key valuation signals for STU:2Y30:

  • Beta: 0.0379
  • GF Value™: €422.95 vs. price of €315.84 (25.3% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the STU:2Y30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bionano Genomics Business Description

Other Exchanges BNGO:USABNGO:Mexico
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score

Get the complete analysis for STU:2Y30

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€315.84
Price
€422.95
GF Value